Blog
RSS FeedPosted by Michael Wonder on 16 Feb 2022
PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments
16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...
Posted by Michael Wonder on 31 Jan 2022
New Zealand Pharmaceutical Schedule - 1 February 2022 update
1 February 2022 - The Febuary 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...
Posted by Michael Wonder on 22 Dec 2021
PHARMAC publishes experts’ advice and seeks views on patient access criteria for COVID-19 treatments
22 December 2021 - PHARMAC is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback ...
Posted by Michael Wonder on 06 Dec 2021
PHARMAC negotiates deal with Pfizer for its promising new oral antiviral treatment for COVID-19
6 December 2021 - PHARMAC has negotiated an agreement with Pfizer for its promising new oral anti-viral treatment to treat ...
Posted by Michael Wonder on 07 Nov 2021
COVID-19: PHARMAC confident with growing stock of drugs to treat virus
7 November 2021 - PHARMAC is growing increasingly confident it is getting close to having enough of the drugs needed to ...
Posted by Michael Wonder on 06 Nov 2021
PHARMAC to fund baricitinib to treat moderate to severe cases of COVID-19
5 November 2021 - PHARMAC has purchased another new medicine, baricitinib, to treat moderate to severe cases of COVID-19, with 500 ...
Posted by Michael Wonder on 31 Oct 2021
PHARMAC negotiates deal for a further COVID-19 treatment
31 October 2021 - PHARMAC has negotiated an agreement with Roche to purchase another COVID-19 treatment. ...
Posted by Michael Wonder on 10 Oct 2021
PHARMAC negotiates deal for molnupiravir to treat COVID-19
11 October 2021 - PHARMAC has negotiated an agreement with supplier MSD to purchase the antiviral molnupiravir. ...
Posted by Michael Wonder on 06 Oct 2021
Where has PHARMAC gone?
7 October 2021 - As debate has intensified over the last year or so about the procurement of New Zealand’s ...
Posted by Michael Wonder on 16 Sep 2021
PHARMAC funds tocilizumab to treat cases of COVID-19
16 September 2021 - PHARMAC is widening funded access to tocilizumab, an immunosuppressive drug used mainly to treat arthritis, to treat ...
Posted by Michael Wonder on 06 Sep 2021
New Zealand’s tocilizumab supply to be paused
6 September 2021 - PHARMAC has today announced that Roche, the global pharmaceutical company which provides tocilizumab, will not provide New ...
Posted by Michael Wonder on 19 May 2021
Government to introduce new law for vaccine after legal challenge
19 May 2021 - The Government will introduce legislation on Wednesday to ensure the COVID-19 vaccination programme can continue, after ...
Posted by Michael Wonder on 12 May 2021
Impacts to medicine supply from India
12 May 2021 - PHARMAC is in constant contact with our suppliers as the impact of COVID-19 on India unfolds. ...
Posted by Michael Wonder on 26 Apr 2021
New Zealand's vaccination program is built on Pfizer and a plan to take it slow
27 April 2021 - All New Zealanders are likely to get the Pfizer COVID-19 vaccine and that clarity has generated a ...